Our top pick for
MacroGenics Inc is a biotechnology business based in the US. MacroGenics shares (MGNX) are listed on the NASDAQ and all prices are listed in US Dollars. MacroGenics employs 370 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$19.05|
|52-week range||$18.16 - $36.48|
|50-day moving average||$21.38|
|200-day moving average||$25.86|
|Wall St. target price||$36.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||-1.96%|
|1 month (2021-09-28)||-7.61%|
|3 months (2021-07-28)||-27.87%|
|6 months (2021-04-28)||-46.02%|
|1 year (2020-10-27)||-10.56%|
|2 years (2019-10-25)||118.71%|
|3 years (2018-10-26)||9.36%|
|5 years (2016-10-27)||23.85|
Valuing MacroGenics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MacroGenics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MacroGenics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.01. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MacroGenics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$118.6 million|
|Gross profit TTM||$-88,318,000|
|Return on assets TTM||-21.55%|
|Return on equity TTM||-45.63%|
|Market capitalisation||$1.2 billion|
TTM: trailing 12 months
There are currently 3.2 million MacroGenics shares held short by investors – that's known as MacroGenics's "short interest". This figure is 1.1% down from 3.2 million last month.
There are a few different ways that this level of interest in shorting MacroGenics shares can be evaluated.
MacroGenics's "short interest ratio" (SIR) is the quantity of MacroGenics shares currently shorted divided by the average quantity of MacroGenics shares traded daily (recently around 1.0 million). MacroGenics's SIR currently stands at 3.08. In other words for every 100,000 MacroGenics shares traded daily on the market, roughly 3080 shares are currently held short.
However MacroGenics's short interest can also be evaluated against the total number of MacroGenics shares, or, against the total number of tradable MacroGenics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MacroGenics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 MacroGenics shares in existence, roughly 50 shares are currently held short) or 0.054% of the tradable shares (for every 100,000 tradable MacroGenics shares, roughly 54 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against MacroGenics.
Find out more about how you can short MacroGenics stock.
We're not expecting MacroGenics to pay a dividend over the next 12 months.
Over the last 12 months, MacroGenics's shares have ranged in value from as little as $18.16 up to $36.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MacroGenics's is 2.2058. This would suggest that MacroGenics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
MacroGenics, Inc. , a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.